The global Inferior Vena Cava (IVC) Filters Market is expected to grow at a CAGR of 9.4% during the forecast period 2022 to 2028. Inferior Vena Cava Filters Market is a device implanted in inferior vena cava, the largest vein in the human body. The inferior vena cava filter is inserted below the kidneys to prevent the risk of pulmonary embolism (PE) and deep vein thrombosis (DVT) when anticoagulation therapy is contraindicated in the patients. The inferior vena cava filters are work by permitting the blood flow around the trapped clot.  The commercially available inferior vena cava filters include temporary filters and pulmonary filters. Global IVC filters market is growing at a healthy CAGR owing to increase in the prevalence of deep vein thrombosis. According to the International Society of Thrombosis and Haemostasis, Inc. (ISTH), approximately 10 Mn cases of venous thromboembolism occur annually around the globe. The most commonly adopted strategies by industry players include new product launches with technological advances, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism market share. For instance, in December 2012, Volcano Corporation acquired Crux Biomedical for developing its inferior vena cava product portfolio. Similarly, in April 2013, Argon Medical Devices, Inc. has acquired Angiotech Interventional Business for the development of inferior vena cava product portfolio. Moreover, favourable initiatives by the regulatory bodies also expected to boost the IVC market. For instance, in May 2014, FDA released the post-market surveillance of IVF filters which provides the implementation of filters and risk of pulmonary embolism.